Clinical Trial and Real-World Evidence Around CAR T-cell Therapy in LBCL

Video

Andrew Ip, MD, and Lori Leslie, MD, review clinical trial and real-world data on the efficacy and survival rates of CAR T-cell therapy in large B-cell lymphoma.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
Related Content
Real-World Results May Differ From Clinical Trials of CAR T-Cell Therapy Use in DLBCL

Real-World Results May Differ From Clinical Trials of CAR T-Cell Therapy Use in DLBCL

Kristie L. Kahl
November 17th 2024
Article

“When thinking about treatment options for refractory DLBCL you consider: Is it safe to give an older patient CAR T-[cell therapy]?,” said Jennifer Amengual, MD.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.

Transposon-Engineered BAFF CAR-T Cells May Elicit Responses in Lymphoma

Roman Fabbricatore
November 13th 2024
Article

Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Phase 2 data support a favorable risk/benefit profile with valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma.

Valemetostat Yields Enduring Responses in Relapsed/Refractory PTCL

Russ Conroy
November 6th 2024
Article

Phase 2 data support a favorable risk/benefit profile with valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma.

Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.

Nivolumab Combo Improves PFS in Stage III/IV Advanced Hodgkin Lymphoma

Russ Conroy
October 17th 2024
Article

Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.